Home Alzheimer’s Disease John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study

John Kuruvilla, MD, on the Implications of the Phase III KEYNOTE-204 Study

Results from the randomized, open-label phase III KEYNOTE-204 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, suggested that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).

In an interview with CancerNetwork®, John Kuruvilla, MD, of the Princess Margaret Cancer Centre, discussed the implications of the phase III KEYNOTE-204 trial and what these findings represent for this patient population. 

Transcription:

It’s been an interesting study to think about because the population is actually both broad and focused in a way, so the real standard in this setting for a long time had been brentuximab vedotin, and that was based on the pivotal trial that had enrolled patients that had had disease progression only following autologous stem…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments